Navigation Links
Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
Date:7/12/2013

SAN DIEGO, July 12, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the appointment of Chetan S. Shah, M.D. to its board of directors.  "We are honored to have Dr. Shah join our board. His wealth of medical and business experience will be instrumental in guiding the future growth and achievement of our organization," stated Aethlon Chairman & CEO Jim Joyce.

(Logo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Dr. Shah is a board certified Otolaryngologist. He is an Advisory Board Member at The Bank of Princeton, and a founder, partner and Board member of the Surgery Center at Hamilton as well as Physician Management Systems and Princeton Eye & Ear. Dr. Shah serves on the board of two other private companies. He holds teaching positions and serves on multiple hospital committees in the area and is on the Audiology and Speech Language Pathology Committee for the State of New Jersey.  Dr. Shah received his Bachelor's degree and Medical Degree from Rutgers University and Robert Wood Johnson Medical School.

"Aethlon Medical's Hemopurifier® is first in class therapeutic device that is a game changer in both the infectious as well as cancer treatment regimen.  As a physician, I am excited at the prospect of being able to help millions of patients worldwide.  As a director, I look forward to building value for all who have patiently supported the company over the past decade," stated Dr. Shah.

About Aethlon Medical

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system.  At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers.  For more information, please visit www.aethlonmedical.com.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's future clinical programs or provide market clearance of the Company's products, future human studies whether revenue or non-revenue generating from either compassionate use or non-compassionate use of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or sepsis therapies or as a standalone cancer or hepatitis C therapy or standalone sepsis therapy, the approval of the Company's technologies or products as a treatment against pandemic threats, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Marc Robins
877.276.2467
mr@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
2. Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
3. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
4. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
6. Aethlon Medical Discloses CEO Interview
7. Aethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
8. Aethlon Medical To Present Today At The 15th International Conference On Dialysis
9. Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board
10. Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
11. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute lymphocytic Leukemia Market ... to their offering.       (Logo: ... Acute Lymphocytic Leukemia Market and Competitive Landscape ... Lymphocytic Leukemia pipeline products, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... A wide variety of national pet product manufacturers, companies and ... Safety Media Showcase Wednesday, May 18 from noon to 8 p.m. at New York City’s ... at new and established home, garden, outdoor and safety pet products in today’s marketplace. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range of ... for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: ... Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, and ...
(Date:5/6/2016)... ... May 06, 2016 , ... Expert ... . , Since launching in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com ... now include pillows, sheets, mattress toppers, bed frames, and more. , Founder and ...
(Date:5/6/2016)... ... May 06, 2016 , ... This Mother’s Day kicks ... everywhere. The 17th annual National Women’s Health Week takes place May 8-May ... Health are combining forces to empower women to make their health a top priority. ...
(Date:5/5/2016)... ... 05, 2016 , ... While the practice and profession of Aging Life Care ... population has on communities and resources. Aging Life Care plays an important role as ... , Aging Life Care is a holistic, client-centered approach to caring for older ...
Breaking Medicine News(10 mins):